Transforming cancer treatment through empowered science

Seattle Genetics was founded in 1998, and since 2001 the company’s stock has been publicly traded on Nasdaq under the symbol SGEN. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer, has resulted in one approved drug and a robust pipeline of programs in clinical development for lymphoma, leukemia, urothelial (bladder) and breast cancer.

Recent News

  • Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma MORE
  • Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting MORE
  • Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma MORE

VIEW ALL NEWS

$55.71

 1.10 (2.01%)

12/13/17  4:00 p.m. ET

NASDAQ | SGEN (Common Stock)

High$56.26
Volume1,320,665
Low$54.20
Mkt Cap$8,018,247,877

Data provided by Nasdaq. Minimum 15 minutes delay

Seattle Genetics Fast Facts

NASDAQSGEN

Common Stock CUSIP812578 102

Fiscal Year Jan. 1 - Dec. 31

State IncorporatedDelaware

Transfer Agent Computershare

STAY CONNECTED

Investor Contact

Peggy Pinkston
Vice President, Investor Relations
investors@seagen.com
425-527-4160

Email Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site.

Get email alerts